Promoter holding
64.27%
SL
Sandor Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Sandorlifesciences: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Sandorlifesciences — 360° Intelligence Report
Generated from MCA filings & public records55/100
Trust Score
Moderate
Sandorlifesciences is assessed as Moderate with a Trust Score of 55/100. Sandorlifesciences is an active private limited indian non-government company incorporated in 2004, operating in the Life Sciences sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.
Report generated on 17 Aug 2026 from the latest processed filings. Sandor Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
55/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
68/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
30/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- Externally credit-rated (D).
Charges position: 6 open (74.31 cr) · 4 satisfied (19.51 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 2 | 48.0 cr |
| State Bank Of India | 3 | 48.0 cr |
| Tata Capital Financial Services Limited | 4 | 48.0 cr |
| Icici Bank Limited | 1 | 48.0 cr |
Compliance Score: 68/100 Moderate
- Company status is Active as per MCA.
- Last balance sheet is for Mar 2021 - filings overdue.
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| TIRUNELVELI PADMANABHAN DEVARAJAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUBRAMANIAN VISHAR VASUDEVAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJEEV SINDHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GUNJAN SINDHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2020 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Sandor Speciality Diagnostics Private Limited
Subsidiaries
-
Group entities
1
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Sandor Speciality Diagnostics Private Limited | Holding Company | 74.00% |
| Sandor Medicaids Private Limited | Associate Company | 74.00% |
Key managerial personnel: RAJEEV SINDHI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 30
Growth signals & trust indicators
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
Statutory filings appear overdue.
6 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence53/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 4 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment39/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 6 open charge(s) of 74.31 cr already registered.
- Compliance gaps should be priced into terms.
Investor view32/100
Limited indicators at present
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events03 Jul 2023
Last AGM held
Annual general meeting
23 Jan 2023
Charge created
State Bank Of India - 3.15 cr
20 Aug 2021
Charge created
Others - 1.86 cr
18 May 2021
Charge satisfied
Tata Capital Financial Services Limited
31 Mar 2021
Latest balance sheet
Filed with ROC
13 Jul 2020
Securities allotted
7500000 Equity Shares Without Differential Rights - 7.50 cr raised
Director ceased
SUBRAMANIAN VISHAR VASUDEVAN
11 Jul 2020
Director appointed
SUBRAMANIAN VISHAR VASUDEVAN (Director)
30 Oct 2019
Charge created
Tata Capital Financial Services Limited - 1.50 cr
16 Sep 2019
Charge created
State Bank Of India - 32.00 cr
25 May 2018
Director ceased
SAMARTH SINDHI
12 Jul 2017
Charge created
Tata Capital Financial Services Limited - 5.00 cr
16 Dec 2016
Director ceased
RAJESH VANKADARA
30 Mar 2016
Charge created
Tata Capital Financial Services Limited - 6.25 cr
15 Mar 2016
Director ceased
SARBESWAR SAHARIAH
10
Key Observations
Auto-generated from the data aboveRevenue declined 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of D from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
3 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Dappros Private Limited | U72900MH2018PTC307728 | Mumbai, Maharashtra, India |
| Srujan Research And Planning Foundation | U74900PN2015NPL155355 | Pune, Maharashtra, India |
| Transcell Oncologics Private Limited | U74999TG2017PTC118680 | Hyderabad, Telangana, India |
| Kyvor | U74900TN2013PTC092565 | Madurai, Tamil Nadu, India |
| Avisa Biotech Private Limited | U24305MH2016PTC285705 | Virar West, Maharashtra, India |
| Intent Design Private Limited | U72200KA2004PTC033712 | Bangalore, Karnataka, India |
| Vincom It Solutions Private Limited | U72502DL2016PTC290323 | New Delhi, Delhi, India |
| Elvikon India Private Limited | U24304TG2017PTC115861 | Ameenpur, Telangana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sandorlifesciences before audits and certifications: compliance score 68/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sandorlifesciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Sandorlifesciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 55/100, distress signals and MSME payment-delay disclosures - know whether Sandorlifesciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Sandorlifesciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sandorlifesciences an active company?
Sandorlifesciences has MCA status “Active” with a compliance score of 68/100 (Moderate).
Is Sandorlifesciences financially healthy?
Sandorlifesciences has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Sandorlifesciences?
Its overall Trust Score is 55/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sandorlifesciences?
The ultimate holding entity is Sandor Speciality Diagnostics Private Limited. 4 active director(s) are on record.
Does Sandorlifesciences have loans or charges against its assets?
6 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.
Is Sandorlifesciences up to date with its ROC filings?
Last balance sheet is for Mar 2021 - filings overdue. Overall compliance score: 68/100 (Moderate).
Is it risky to lend to Sandorlifesciences?
Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
